The Multicompartmental P32/gClqR As a New Target for Antibody-based Tumor Targeting Strategies

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2010 Dec 16

PMID 21156793

Citations 24

Authors

David Sanchez-Martin

Angel M Cuesta

Valentina Fogal

Erkki Ruoslahti

Luis Alvarez-Vallina

Affiliations

Soon will be listed here.

Abstract

Tumor-associated cell surface antigens and tumor-associated vascular markers have been used as a target for cancer intervention strategies. However, both types of targets have limitations due to accessibility, low and/or heterogeneous expression, and presence of tumor-associated serum antigen. It has been previously reported that a mitochondrial/cell surface protein, p32/gC1qR, is the receptor for a tumor-homing peptide, LyP-1, which specifically recognizes an epitope in tumor cells, tumor lymphatics, and tumor-associated macrophages/myeloid cells. Using antibody phage technology, we have generated an anti-p32 human monoclonal antibody (2.15). The 2.15 antibody, expressed in single-chain fragment variable and in trimerbody format, was then characterized in vivo using mice grafted subcutaneously with MDA-MB-231 human breast cancers cells, revealing a highly selective tumor uptake. The intratumoral distribution of the antibody was consistent with the expression pattern of p32 in the surface of some clusters of cells. These results demonstrate the potential of p32 for antibody-based tumor targeting strategies and the utility of the 2.15 antibody as targeting moiety for the selective delivery of imaging and therapeutic agents to tumors.

Citing Articles

Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis.

Bi Q, Nie J, Wu Q, Sun L, Zhu S, Bai J Med Oncol. 2025; 42(3):60.

PMID: 39891862 DOI: 10.1007/s12032-025-02604-9.

gC1qR: A New Target for Cancer Immunotherapy.

Lei Y, Li X, Qin D, Zhang Y, Wang Y Front Immunol. 2023; 14:1095943.

PMID: 36776869 PMC: 9909189. DOI: 10.3389/fimmu.2023.1095943.

C1QBP Mediates Breast Cancer Cell Proliferation and Growth via Multiple Potential Signalling Pathways.

Scully O, Shyamasundar S, Matsumoto K, Dheen S, Yip G, Bay B Int J Mol Sci. 2023; 24(2).

PMID: 36674861 PMC: 9864289. DOI: 10.3390/ijms24021343.

C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response.

Wang Q, Chai D, Sobhani N, Sun N, Neeli P, Zheng J Front Physiol. 2022; 13:1012112.

PMID: 36467687 PMC: 9713694. DOI: 10.3389/fphys.2022.1012112.

C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse.

Yang L, Zhang C, Yang M, Zhang X, Liu H, Luo C Blood. 2022; 141(7):766-786.

PMID: 36322939 PMC: 10651790. DOI: 10.1182/blood.2022017046.

References

Oiki S, Okada Y . C1q induces chemotaxis and K+ conductance activation coupled to increased cytosolic Ca2+ in mouse fibroblasts. J Immunol. 1988; 141(9):3177-85. View

Lynch N, Reid K, van den Berg R, Daha M, Leigh L, Ghebrehiwet B . Characterisation of the rat and mouse homologues of gC1qBP, a 33 kDa glycoprotein that binds to the globular 'heads' of C1q. FEBS Lett. 1997; 418(1-2):111-4. DOI: 10.1016/s0014-5793(97)01348-3. View

Eggleton P, Ghebrehiwet B, Sastry K, Coburn J, Zaner K, Reid K . Identification of a gC1q-binding protein (gC1q-R) on the surface of human neutrophils. Subcellular localization and binding properties in comparison with the cC1q-R. J Clin Invest. 1995; 95(4):1569-78. PMC: 295648. DOI: 10.1172/JCI117830. View

Peerschke E, Smyth S, Teng E, Dalzell M, Ghebrehiwet B . Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q. J Immunol. 1996; 157(9):4154-8. View

Fogal V, Zhang L, Krajewski S, Ruoslahti E . Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 2008; 68(17):7210-8. PMC: 2562323. DOI: 10.1158/0008-5472.CAN-07-6752. View

Steffen A, Orlova A, Wikman M, Nilsson F, Stahl S, Adams G . Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging. 2006; 33(6):631-8. DOI: 10.1007/s00259-005-0012-3. View

Braun L, Ghebrehiwet B, Cossart P . gC1q-R/p32, a C1q-binding protein, is a receptor for the InlB invasion protein of Listeria monocytogenes. EMBO J. 2000; 19(7):1458-66. PMC: 310215. DOI: 10.1093/emboj/19.7.1458. View

Sanz L, Kristensen P, Blanco B, Facteau S, Russell S, Winter G . Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 2002; 9(15):1049-53. DOI: 10.1038/sj.gt.3301725. View

Kristensen P, Winter G . Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des. 1998; 3(5):321-8. DOI: 10.1016/S1359-0278(98)00044-3. View

10.

Mahdi F, Shariat-Madar Z, Todd 3rd R, Figueroa C, Schmaier A . Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood. 2001; 97(8):2342-50. DOI: 10.1182/blood.v97.8.2342. View

11.

Griffiths A, Williams S, Hartley O, Tomlinson I, Waterhouse P, Crosby W . Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994; 13(14):3245-60. PMC: 395221. DOI: 10.1002/j.1460-2075.1994.tb06626.x. View

12.

Harries M, Smith I . The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002; 9(2):75-85. DOI: 10.1677/erc.0.0090075. View

13.

Vogel C, Bischof-Delaloye A, Mach J, Pelegrin A, Hardman N, DELALOYE B . Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer. 1993; 68(4):684-90. PMC: 1968595. DOI: 10.1038/bjc.1993.410. View

14.

Cuesta A, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-Vallina L . Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010; 28(7):355-62. DOI: 10.1016/j.tibtech.2010.03.007. View

15.

Silacci M, Brack S, Spath N, Buck A, Hillinger S, Arni S . Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel. 2006; 19(10):471-8. DOI: 10.1093/protein/gzl033. View

16.

Cuesta A, Sanchez-Martin D, Sanz L, Bonet J, Compte M, Kremer L . In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One. 2009; 4(4):e5381. PMC: 2670539. DOI: 10.1371/journal.pone.0005381. View

17.

van den Berg R, Prins F, Lynch N, Schwaeble W, van Es L, Daha M . Intracellular localization of the human receptor for the globular domains of C1q. J Immunol. 1997; 158(8):3909-16. View

18.

Eggleton P, Tenner A, Reid K . C1q receptors. Clin Exp Immunol. 2000; 120(3):406-12. PMC: 1905565. DOI: 10.1046/j.1365-2249.2000.01218.x. View

19.

Jacobsson H, Wallin G, Werner S, Larsson S . Technetium-99m methoxyisobutylisonitrile localizes an ectopic ACTH-producing tumour: case report and review of the literature. Eur J Nucl Med. 1994; 21(6):582-6. DOI: 10.1007/BF00173046. View

20.

Carter P, Bedouelle H, Winter G . Improved oligonucleotide site-directed mutagenesis using M13 vectors. Nucleic Acids Res. 1985; 13(12):4431-43. PMC: 321798. DOI: 10.1093/nar/13.12.4431. View